Source link : https://www.newshealth.biz/health-news/new-monoclonal-antibody-class-shows-promise-for-migraine/
A potential first-in-class therapy for migraine prevention has shown promise in a phase 2a proof-of-concept study, with a single infusion reducing migraine frequency over 4 weeks. The drug Lu AG09222 from Lundbeck is an investigational monoclonal antibody that targets a pathway in migraine that is distinct from pathways targeted by the calcitonin gene-related peptide (CGRP) […]
Author : News Health
Publish date : 2024-09-06 12:37:57
Copyright for syndicated content belongs to the linked Source.
Categories